Tests remigromig eye injections in adults with wet macular degeneration or BRVO

Trial details

Who runs it

EyeBiotech Ltd.

Trial code

NCT07205887

Record updated

20 October 2026

Original description

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).Read full original descriptionShow less

A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).

The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.

All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.

Inclusion: Key General Inclusion Criteria; Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity; Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria; Be ≥ 50 years of age; Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal/extrafoveal CNV with foveal involvement; For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment; Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria; Be ≥ 50 years of age; Have subfoveal CNV secondary to AMD or juxtafoveal/extrafoveal CNV with foveal involvement at initial screening; For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2; Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria; Be diagnosed with BRVO in the study eye; Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO; Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening.

Exclusion: Have had previous thermal subfoveal laser therapy in the study eye; Have had previous photodynamic therapy with Visudyne in the study eye; Key BRVO-specific Exclusion Criteria; History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening; Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome); Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone); Key NVAMD-specific Exclusion Criteria; Key General Exclusion Criteria; Pregnant or breastfeeding; Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening; Have active iris or angle neovascularization or neovascular glaucoma in the study eye.

ClinicalTrials.gov NCT07205887